STAT3
signal transducer and activator of transcription 3, the group of SH2 domain containing
Basic information
Region (hg38): 17:42313323-42388540
Links
Phenotypes
GenCC
Source:
- hyper-IgE recurrent infection syndrome 1, autosomal dominant (Strong), mode of inheritance: AD
- STAT3-related early-onset multisystem autoimmune disease (Strong), mode of inheritance: AD
- hyper-IgE recurrent infection syndrome 1, autosomal dominant (Supportive), mode of inheritance: AD
- permanent neonatal diabetes mellitus (Supportive), mode of inheritance: AD
- STAT3-related early-onset multisystem autoimmune disease (Supportive), mode of inheritance: AD
- hyper-IgE recurrent infection syndrome 1, autosomal dominant (Strong), mode of inheritance: AD
- STAT3-related early-onset multisystem autoimmune disease (Strong), mode of inheritance: AD
- STAT3-related early-onset multisystem autoimmune disease (Definitive), mode of inheritance: AD
- hyper-IgE recurrent infection syndrome 1, autosomal dominant (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Hyper-IgE recurrent infection syndrome 1, autosomal dominant; Autoimmune disease, multisystem, infantile onset 1 | AD | Allergy/Immunology/Infectious; Cardiovascular; Oncologic | In Hyper-IgE recurrent infection syndrome, among other manifestations, individuals may suffer recurrent mucocutaneous and pulmonary infections, and antintiinfectious prophylaxis (eg, antibiotics, antifungals, and IgG infusions), as well as early and aggressive treatment of infections may be beneficial; The condition may include vascular anomalies, and awareness may be beneficial in management; Individuals may also have susceptibility to malignancies such as non-Hodgkin lymphoma, and awareness may allow early diagnosis and treatment; In Autoimmune disease, multisystem, infantile onset, individuals have been described with immunodeficiency, and awareness may allow antiinfectious prophylaxis as well as early and aggressive treatment of infections; Awarness of sequelae of autoimmune disease (eg, resulting in hypothyroidism) may allow early management of such manifestations | Allergy/Immunology/Infectious; Cardiovascular; Dermatologic; Musculoskeletal; Oncologic | 4161105; 5059313; 6806658; 10053178; 17881745; 17676033; 17942886; 21703716; 22084479; 22751495; 25038750 |
ClinVar
This is a list of variants' phenotypes submitted to
- Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function (247 variants)
- not provided (160 variants)
- STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant (150 variants)
- Hyper-IgE recurrent infection syndrome 1, autosomal dominant (94 variants)
- not specified (52 variants)
- STAT3-related early-onset multisystem autoimmune disease (23 variants)
- Hyper-IgE syndrome (12 variants)
- Inherited Immunodeficiency Diseases (6 variants)
- STAT3-related condition (4 variants)
- Inborn genetic diseases (3 variants)
- Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3-related early-onset multisystem autoimmune disease (3 variants)
- STAT3-Related Conditions (2 variants)
- Malignant lymphoma, large B-cell, diffuse (1 variants)
- EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma (1 variants)
- See cases (1 variants)
- STAT3-related early-onset multisystem autoimmune disease;Hyper-IgE recurrent infection syndrome 1, autosomal dominant (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the STAT3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
|---|---|---|---|---|---|---|
| synonymous | 83 | 10 | 97 | |||
| missense | 26 | 44 | 135 | 14 | 223 | |
| nonsense | 3 | |||||
| start loss | 0 | |||||
| frameshift | 9 | |||||
| inframe indel | 5 | |||||
| splice donor/acceptor (+/-2bp) | 7 | |||||
| splice region ? | 18 | 33 | 3 | 54 | ||
| non coding ? | 43 | 82 | 63 | 188 | ||
| Total | 30 | 48 | 198 | 179 | 77 |
Highest pathogenic variant AF is 0.00000658
Variants in STAT3
This is a list of pathogenic ClinVar variants found in the STAT3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
| Position | Type | Phenotype | Significance | ClinVar |
|---|---|---|---|---|
| 17-42313400-AAG-A | Hyper-IgE syndrome | Uncertain significance (Jun 14, 2016) | ||
| 17-42313401-AG-A | Hyper-IgE syndrome | Uncertain significance (Jun 14, 2016) | ||
| 17-42313404-C-CA | Hyper-IgE syndrome | Uncertain significance (Jun 14, 2016) | ||
| 17-42313490-C-A | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 13, 2018) | ||
| 17-42313598-T-C | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Benign (Jan 13, 2018) | ||
| 17-42313601-G-A | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 13, 2018) | ||
| 17-42313743-C-T | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 13, 2018) | ||
| 17-42313775-T-C | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Apr 27, 2017) | ||
| 17-42313814-T-C | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Benign (Jan 12, 2018) | ||
| 17-42313854-G-A | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 12, 2018) | ||
| 17-42313892-T-C | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Benign (Jan 13, 2018) | ||
| 17-42313895-G-A | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 12, 2018) | ||
| 17-42313895-G-C | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 13, 2018) | ||
| 17-42314070-A-G | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 12, 2018) | ||
| 17-42314072-G-A | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 13, 2018) | ||
| 17-42314074-G-A | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Benign (Jan 12, 2018) | ||
| 17-42314100-G-A | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 12, 2018) | ||
| 17-42314228-C-T | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Benign (Jan 12, 2018) | ||
| 17-42314248-C-T | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 12, 2018) | ||
| 17-42314330-G-C | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 13, 2018) | ||
| 17-42314362-C-G | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Benign (Jan 13, 2018) | ||
| 17-42314420-T-C | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Benign (Jan 13, 2018) | ||
| 17-42314429-T-C | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Benign (Jan 12, 2018) | ||
| 17-42314475-G-A | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 12, 2018) | ||
| 17-42314479-C-T | Hyper-IgE recurrent infection syndrome 1, autosomal dominant | Uncertain significance (Jan 13, 2018) |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| STAT3 | protein_coding | protein_coding | ENST00000264657 | 23 | 75245 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 1.00 | 6.67e-8 | 125723 | 0 | 1 | 125724 | 0.00000398 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 4.99 | 131 | 419 | 0.313 | 0.0000248 | 5082 |
| Missense in Polyphen | 28 | 152.38 | 0.18375 | 1952 | ||
| Synonymous | 0.239 | 158 | 162 | 0.976 | 0.00000979 | 1430 |
| Loss of Function | 6.43 | 1 | 50.1 | 0.0199 | 0.00000255 | 566 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.00 | 0.00 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.00000879 | 0.00000879 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.00 | 0.00 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors (PubMed:10688651, PubMed:12359225, PubMed:12873986, PubMed:15194700, PubMed:17344214, PubMed:18242580, PubMed:23084476). Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene (PubMed:17344214). May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:12873986). Binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes (PubMed:12359225). Activated by IL31 through IL31RA (PubMed:15194700). Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): deacetylation and oxidation of lysine residues by LOXL3, leads to disrupt STAT3 dimerization and inhibit its transcription activity (PubMed:28065600). Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1 (PubMed:17344214). Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation (By similarity). May play an apoptotic role by transctivating BIRC5 expression under LEP activation (PubMed:18242580). Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity (PubMed:23084476). Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion (By similarity). {ECO:0000250|UniProtKB:P42227, ECO:0000269|PubMed:10688651, ECO:0000269|PubMed:12359225, ECO:0000269|PubMed:12873986, ECO:0000269|PubMed:15194700, ECO:0000269|PubMed:17344214, ECO:0000269|PubMed:18242580, ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:28065600}.;
- Disease
- DISEASE: Hyperimmunoglobulin E recurrent infection syndrome, autosomal dominant (AD-HIES) [MIM:147060]: A rare disorder of immunity and connective tissue characterized by immunodeficiency, chronic eczema, recurrent Staphylococcal infections, increased serum IgE, eosinophilia, distinctive coarse facial appearance, abnormal dentition, hyperextensibility of the joints, and bone fractures. {ECO:0000269|PubMed:17676033, ECO:0000269|PubMed:17881745, ECO:0000269|PubMed:23342295, ECO:0000269|PubMed:26293184}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Autoimmune disease, multisystem, infantile-onset, 1 (ADMIO1) [MIM:615952]: A disorder characterized by early childhood onset of a spectrum of autoimmune manifestations affecting multiple organs, including insulin-dependent diabetes mellitus and autoimmune enteropathy or celiac disease. Other features include short stature, non-specific dermatitis, hypothyroidism, autoimmune arthritis, and delayed puberty. {ECO:0000269|PubMed:25038750, ECO:0000269|PubMed:28073828}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Non-small cell lung cancer - Homo sapiens (human);Adipocytokine signaling pathway - Homo sapiens (human);Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human);Insulin resistance - Homo sapiens (human);AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human);HIF-1 signaling pathway - Homo sapiens (human);Jak-STAT signaling pathway - Homo sapiens (human);Acute myeloid leukemia - Homo sapiens (human);Inflammatory bowel disease (IBD) - Homo sapiens (human);FoxO signaling pathway - Homo sapiens (human);Chemokine signaling pathway - Homo sapiens (human);Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human);Necroptosis - Homo sapiens (human);Th17 cell differentiation - Homo sapiens (human);Toxoplasmosis - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);Prolactin signaling pathway - Homo sapiens (human);MicroRNAs in cancer - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Viral carcinogenesis - Homo sapiens (human);Hepatitis C - Homo sapiens (human);Hepatitis B - Homo sapiens (human);Measles - Homo sapiens (human);Epstein-Barr virus infection - Homo sapiens (human);Busulfan Pathway, Pharmacodynamics;Pancreatic cancer - Homo sapiens (human);EGFR Inhibitor Pathway, Pharmacodynamics;JAK-STAT-Core;IL-5 Signaling Pathway;Androgen receptor signaling pathway;Physiological and Pathological Hypertrophy of the Heart;MicroRNAs in cardiomyocyte hypertrophy;TFs Regulate miRNAs related to cardiac hypertrophy;Cell Differentiation - Index expanded;Leptin signaling pathway;Cell Differentiation - Index;Human Thyroid Stimulating Hormone (TSH) signaling pathway;Prolactin Signaling Pathway;Regulation of Microtubule Cytoskeleton;IL-7 Signaling Pathway;IL17 signaling pathway;IL-9 Signaling Pathway;Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway;Androgen Receptor Network in Prostate Cancer;AGE-RAGE pathway;Interleukin-11 Signaling Pathway;Adipogenesis;Oncostatin M Signaling Pathway;Brain-Derived Neurotrophic Factor (BDNF) signaling pathway;JAK-STAT;Mammary gland development pathway - Involution (Stage 4 of 4);Dopaminergic Neurogenesis;IL-3 Signaling Pathway;TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer;Estrogen Receptor Pathway;Nuclear Receptors Meta-Pathway;Kit receptor signaling pathway;Signaling of Hepatocyte Growth Factor Receptor;Rac1-Pak1-p38-MMP-2 pathway;POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation;IL-6 signaling pathway;Hepatitis C and Hepatocellular Carcinoma;IL-4 Signaling Pathway;VEGFA-VEGFR2 Signaling Pathway;Development of pulmonary dendritic cells and macrophage subsets;Chemokine signaling pathway;ESC Pluripotency Pathways;Leptin Insulin Overlap;PDGFR-beta pathway;HDAC6 interactions;Prion disease pathway;Pathways in clear cell renal cell carcinoma;MET in type 1 papillary renal cell carcinoma;EGF-EGFR Signaling Pathway;IL-2 Signaling Pathway;TGF-beta Receptor Signaling;EPO Receptor Signaling;Interferon type I signaling pathways;Notch Signaling Pathway;Serotonin Receptor 2 and STAT3 Signaling;Developmental Biology;Signaling by PTK6;RAGE;Interleukin-4 and 13 signaling;Notch;Interleukin-12 family signaling;Disease;Signal Transduction;Signaling by Interleukins;bioactive peptide induced signaling pathway;egf signaling pathway;stat3 signaling pathway;Growth hormone receptor signaling;il22 soluble receptor signaling pathway;il 6 signaling pathway;erk1/erk2 mapk signaling pathway;role of erbb2 in signal transduction and oncology;Prolactin;Cytokine Signaling in Immune system;JAK STAT MolecularVariation 1;IL12 signaling mediated by STAT4;Metabolism of proteins;Signaling by PDGF;Interleukin-20 family signaling;Chaperonin-mediated protein folding;Oncostatin_M;Immune System;Association of TriC/CCT with target proteins during biosynthesis;IFN alpha signaling;KitReceptor;IL-10 signaling;Fibroblast growth factor-1;PTK6 Activates STAT3;BCR;AndrogenReceptor;IL-23 signaling;pdgf signaling pathway;IL-6 signaling;POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation;Interleukin-23 signaling;tpo signaling pathway;Signaling by NTRK1 (TRKA);Signaling by NTRKs;EGFR1;Interleukin-10 signaling;MET activates STAT3;CXCR4-mediated signaling events;ErbB1 downstream signaling;JAK STAT MolecularVariation 2;Signalling to STAT3;Signaling events mediated by TCPTP;JAK STAT pathway and regulation;IL2;LIF signaling;Signaling by Leptin;Protein folding;IL11;Signaling by Non-Receptor Tyrosine Kinases;EPO signaling;IL2-mediated signaling events;Gastrin;Downstream signal transduction;IL4;Transcriptional regulation of pluripotent stem cells;Signaling by SCF-KIT;Signaling by FGFR in disease;IL5;Leptin;Interleukin-27 signaling;IL6;IL-7;Signaling by cytosolic FGFR1 fusion mutants;FGFR1 mutant receptor activation;Signaling by FGFR1 in disease;Signaling by MET;Signaling by Receptor Tyrosine Kinases;TPO signaling;BMP2 signaling TGF-beta MV;IL9;ErbB2/ErbB3 signaling events;Notch-mediated HES/HEY network;IL23-mediated signaling events;GMCSF-mediated signaling events;IL27-mediated signaling events;RAC1 signaling pathway;Neurotrophic factor-mediated Trk receptor signaling;Diseases of signal transduction;Signaling events mediated by Stem cell factor receptor (c-Kit);PDGFR-beta signaling pathway;Signaling events mediated by PTP1B;Signaling events mediated by HDAC Class I;Interleukin-6 signaling;Interleukin-6 family signaling;IL6-mediated signaling events;FGF signaling pathway;IL12-mediated signaling events;TSLP
(Consensus)
Recessive Scores
- pRec
- 0.981
Intolerance Scores
- loftool
- 0.0359
- rvis_EVS
- -0.49
- rvis_percentile_EVS
- 22.36
Haploinsufficiency Scores
- pHI
- 0.983
- hipred
- Y
- hipred_score
- 0.783
- ghis
- 0.550
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 1.00
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Stat3
- Phenotype
- endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; muscle phenotype; neoplasm; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; respiratory system phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; skeleton phenotype; renal/urinary system phenotype; immune system phenotype; vision/eye phenotype;
Zebrafish Information Network
- Gene name
- stat3
- Affected structure
- Muller cell
- Phenotype tag
- abnormal
- Phenotype quality
- proliferative
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;temperature homeostasis;eye photoreceptor cell differentiation;regulation of transcription, DNA-templated;regulation of transcription by RNA polymerase II;protein import into nucleus;acute-phase response;inflammatory response;signal transduction;JAK-STAT cascade;nervous system development;aging;cell population proliferation;negative regulation of cell population proliferation;positive regulation of gene expression;negative regulation of hydrogen peroxide biosynthetic process;viral process;phosphorylation;cytokine-mediated signaling pathway;sexual reproduction;positive regulation of cell migration;intracellular receptor signaling pathway;response to estradiol;cellular response to hormone stimulus;leptin-mediated signaling pathway;somatic stem cell population maintenance;miRNA mediated inhibition of translation;interleukin-15-mediated signaling pathway;interleukin-7-mediated signaling pathway;interleukin-9-mediated signaling pathway;interleukin-21-mediated signaling pathway;interleukin-23-mediated signaling pathway;regulation of multicellular organism growth;positive regulation of tyrosine phosphorylation of STAT protein;glucose homeostasis;eating behavior;mRNA transcription by RNA polymerase II;negative regulation of apoptotic process;cellular response to leptin stimulus;response to leptin;positive regulation of interleukin-6 biosynthetic process;response to ethanol;positive regulation of erythrocyte differentiation;positive regulation of Notch signaling pathway;positive regulation of angiogenesis;negative regulation of glycolytic process;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;regulation of mitochondrial membrane permeability;astrocyte differentiation;modulation of chemical synaptic transmission;positive regulation of NF-kappaB transcription factor activity;regulation of cell cycle;radial glial cell differentiation;regulation of feeding behavior;growth hormone receptor signaling pathway;JAK-STAT cascade involved in growth hormone signaling pathway;interleukin-6-mediated signaling pathway;interleukin-27-mediated signaling pathway;interleukin-35-mediated signaling pathway;cellular response to cytokine stimulus;cellular response to organic cyclic compound;T-helper 17 cell lineage commitment;energy homeostasis;postsynapse to nucleus signaling pathway;negative regulation of neuron death;positive regulation of growth factor dependent skeletal muscle satellite cell proliferation;positive regulation of pri-miRNA transcription by RNA polymerase II;positive regulation of metalloendopeptidase activity;positive regulation of vascular endothelial cell proliferation;positive regulation of gene silencing by miRNA;negative regulation of stem cell differentiation;positive regulation of ATP biosynthetic process;negative regulation of neuron migration
- Cellular component
- nuclear chromatin;nucleus;nucleoplasm;cytoplasm;mitochondrial inner membrane;cytosol;plasma membrane;postsynaptic density;RNA polymerase II transcription factor complex;Schaffer collateral - CA1 synapse;glutamatergic synapse
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;RNA polymerase II repressing transcription factor binding;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA binding;DNA-binding transcription factor activity;nuclear receptor activity;protein binding;transcription factor binding;protein kinase binding;protein phosphatase binding;chromatin DNA binding;CCR5 chemokine receptor binding;glucocorticoid receptor binding;identical protein binding;protein homodimerization activity;transcription regulatory region DNA binding;protein dimerization activity